Caldwell Trust Co Decreases Position in Novo Nordisk A/S $NVO

Caldwell Trust Co lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 87.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,667 shares of the company’s stock after selling 12,010 shares during the period. Caldwell Trust Co’s holdings in Novo Nordisk A/S were worth $93,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of NVO. True Wealth Design LLC lifted its position in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the last quarter. NewSquare Capital LLC grew its holdings in shares of Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. purchased a new position in shares of Novo Nordisk A/S in the second quarter worth $37,000. Maseco LLP bought a new stake in Novo Nordisk A/S during the 2nd quarter valued at $39,000. Finally, Copeland Capital Management LLC boosted its position in Novo Nordisk A/S by 47.3% during the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after buying an additional 186 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Amazon Pharmacy began offering Novo Nordisk’s new Wegovy pill through insurance plans and a cash-pay option, expanding U.S. distribution and making the first-ever oral GLP‑1 from Novo more accessible to patients — a direct demand and revenue catalyst. Amazon Pharmacy offers Novo Nordisk’s Wegovy pill
• Positive Sentiment: Major retail pharmacy availability reported by CNBC/MSN increases distribution visibility and could shorten the time to volume adoption for the Wegovy pill, supporting revenue upside versus slower clinic-based rollouts. Amazon Pharmacy starts offering Novo Nordisk’s Wegovy weight-loss pill
• Positive Sentiment: Investor research pieces flag Novo as a top pick for 2026 and highlight the FDA‑approved Wegovy pill as a growth catalyst; analysts note robust margins and free cash flow potential (but also cite pricing and competition risks). This supportive analyst tone can lift sentiment and trading interest. Novo Nordisk: A Pill For Growth
• Neutral Sentiment: The JPMorgan Healthcare Conference will put pharma pipeline updates and potential M&A back in focus; Novo may benefit from heightened investor attention but concrete impacts depend on announcements made at the event. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Marketing and PR activities — e.g., a public conversation on weight stigma at a major NYC commuter hub — help brand and patient engagement but are unlikely to move near-term revenue materially. Novo Nordisk conducts a new conversation on weight stigma at major NYC commuter hub
• Neutral Sentiment: Recent price commentary (Zacks note on a modest prior-day gain) reflects momentum but is informational rather than a fundamental driver. Novo Nordisk (NVO) Surpasses Market Returns

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $58.85 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a 50 day moving average price of $49.65 and a 200-day moving average price of $55.40. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The firm has a market capitalization of $262.78 billion, a PE ratio of 17.11 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The company had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analyst Weigh In

NVO has been the subject of a number of analyst reports. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 3rd. HSBC reaffirmed a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Finally, Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a report on Monday, October 27th. They set an “underperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eleven have issued a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $56.21.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.